세계의 다발성 경화증 치료 시장 보고서(2025년)

Multiple sclerosis (MS) treatment encompasses medical strategies and therapies designed to manage symptoms, slow disease progression, and enhance the quality of life for individuals with MS, a chronic autoimmune condition that impacts the central nervous system. These treatments include disease-modifying therapies (DMTs) and symptomatic interventions that address issues such as fatigue, muscle spasms, and mobility difficulties. The primary goal of MS treatment is to support neurological function and improve patients' overall well-being.

Key types of MS treatments include immunomodulators, corticosteroids, symptomatic therapies, monoclonal antibodies, and oral medications. Immunomodulators, such as interferon beta and glatiramer acetate, work by modifying immune system activity to reduce inflammation and prevent relapses. MS-related conditions include clinically isolated syndrome, relapsing-remitting MS, primary progressive MS, and secondary progressive MS. Treatment delivery methods include oral, injectable, and intravenous routes, and these are distributed through hospital pharmacies, retail pharmacies, and online pharmacies. The treatments cater to various end users, including hospitals, specialty clinics, homecare settings, and others.

The multiple sclerosis treatment market research report is one of a series of new reports from The Business Research Company that provides multiple sclerosis treatment market statistics, including the multiple sclerosis treatment industry's global market size, regional shares, competitors with the multiple sclerosis treatment market share, detailed multiple sclerosis treatment market segments, market trends and opportunities, and any further data you may need to thrive in the multiple sclerosis treatment industry. This multiple sclerosis treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The multiple sclerosis treatment market size has grown strongly in recent years. It will grow from $24.86 billion in 2024 to $26.13 billion in 2025 at a compound annual growth rate (CAGR) of 5.1%. This growth during the historical period was driven by heightened awareness of early MS symptoms, expanded access to disease-modifying therapies, rising incidence of autoimmune disorders, improved neurological healthcare infrastructure, and growing use of immunomodulatory drugs.

The multiple sclerosis treatment market size is expected to see steady growth in the next few years. It will grow to $31.55 billion in 2029 at a compound annual growth rate (CAGR) of 4.8%. This anticipated growth is attributed to increasing approvals of novel monoclonal antibodies, heightened demand for personalized MS treatments, enhanced focus on managing neurodegenerative diseases, wider use of telemedicine in MS care, and a shift toward minimally invasive treatment approaches. Notable trends expected in the forecast period include advancements in remote monitoring technologies, the development of remyelination therapies, exploration of gut-brain axis approaches, the integration of digital biomarkers, and innovation in digital therapeutics.

The increasing prevalence of neurological disorders is anticipated to drive the growth of the multiple sclerosis treatment market. Neurological disorders are conditions that impact the brain, spinal cord, and nerves, resulting in challenges with movement, communication, behavior, or bodily functions. This rise in neurological conditions is primarily attributed to an aging population, as longer life expectancies heighten the risk of age-related disorders like Alzheimer's disease. Multiple sclerosis treatments play a crucial role in managing such neurological issues by modulating the immune system to reduce inflammation, minimize nerve damage, and alleviate symptoms, ultimately enhancing patients' quality of life. For example, in October 2023, the World Federation of Neurology, a UK-based organization representing national neurological societies, reported that over 40% of the global population is currently affected by some form of neurological condition, with this figure expected to nearly double by 2050. As a result, the rising prevalence of neurological disorders is significantly contributing to the expansion of the multiple sclerosis treatment market.

Companies operating in the multiple sclerosis treatment space are increasingly focusing on the development of advanced therapies, such as monoclonal antibody drugs, to improve treatment outcomes and efficacy. Monoclonal antibodies are lab-engineered molecules designed to target specific antigens, and in the context of multiple sclerosis, they work by minimizing inflammation and protecting nerve fibers from immune cell attacks, thereby slowing disease progression. For instance, in February 2024, Roche Pharma India, an Indian pharmaceutical company, launched Ocrevus (Ocrelizumab) to treat multiple sclerosis. This drug specifically targets CD20-positive B cells to reduce inflammation and nerve damage. It is the first therapy approved for both relapsing and primary progressive forms of MS and is known to significantly lower relapse rates and slow disability progression with the added benefit of biannual infusions.

In March 2024, Juvise Pharmaceuticals, a pharmaceutical company based in France, acquired a multiple sclerosis drug from Actelion Pharmaceuticals Ltd. for an undisclosed amount. This acquisition aims to broaden Juvise Pharmaceuticals' neurology portfolio beyond the US and Canadian markets, while also involving financial support from Bpifrance and Pemberton to back its future growth strategies. Actelion Pharmaceuticals Ltd., based in Switzerland, is a pharmaceutical company actively engaged in multiple sclerosis treatment development.

Major players in the multiple sclerosis treatment market are Johnson & Johnson Services Inc., F. Hoffmann-La Roche Ltd, Merck And Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, GlaxoSmithKline plc, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Mylan N.V., Biogen Inc., UCB S.A., Mallinckrodt Pharmaceuticals, Acorda Therapeutics Inc., Adamas Pharmaceuticals Inc., Mapi Pharma Ltd., TG Therapeutics Inc., Atara Biotherapeutics Inc.

North America was the largest region in the multiple sclerosis treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in multiple sclerosis treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the multiple sclerosis treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The multiple sclerosis treatment market consists of sales of products including disease-modifying therapies, synthetic polypeptides, cannabinoid-based therapies, interferon beta products, and plasma exchange. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Multiple Sclerosis Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on multiple sclerosis treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for multiple sclerosis treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The multiple sclerosis treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Treatment Type: Immunomodulators; Corticosteroids; Symptomatic Treatments; Monoclonal Antibodies; Oral Therapies
• 2) By DiseaseType: Clinically Isolated Syndrome; Relapse-Remitting Multiple Sclerosis; Primary Progressive Multiple Sclerosis; Secondary Progressive Multiple Sclerosis
• 3) By Route Of Administration: Oral; Injectable; Intravenous
• 4) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
• 5) By End-Users: Hospitals; Specialty Clinics; Homecare; Other End-Users

Subsegments

• 1) By Immunomodulators: Interferon Beta-1A; Interferon Beta-1B; Glatiramer Acetate
• 2) By Corticosteroids: Methylprednisolone; Prednisone; Dexamethasone
• 3) By Symptomatic Treatments: Muscle Relaxants; Antidepressants; Anticonvulsants; Bladder Dysfunction Drugs
• 4) By Monoclonal Antibodies: Natalizumab; Ocrelizumab; Alemtuzumab; Ofatumumab
• 5) By Oral Therapies: Fingolimod; Dimethyl Fumarate; Teriflunomide; Cladribine; Siponimod
• Companies Mentioned: Johnson & Johnson Services Inc.; F. Hoffmann-La Roche Ltd; Merck And Co. Inc.; AbbVie Inc.; Bayer AG
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Multiple Sclerosis Treatment Market Characteristics

3. Multiple Sclerosis Treatment Market Trends And Strategies

4. Multiple Sclerosis Treatment Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Multiple Sclerosis Treatment Growth Analysis And Strategic Analysis Framework

• 5.1. Global Multiple Sclerosis Treatment PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Multiple Sclerosis Treatment Market Growth Rate Analysis
• 5.4. Global Multiple Sclerosis Treatment Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Multiple Sclerosis Treatment Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Multiple Sclerosis Treatment Total Addressable Market (TAM)

6. Multiple Sclerosis Treatment Market Segmentation

• 6.1. Global Multiple Sclerosis Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Immunomodulators
• Corticosteroids
• Symptomatic Treatments
• Monoclonal Antibodies
• Oral Therapies
• 6.2. Global Multiple Sclerosis Treatment Market, Segmentation By DiseaseType, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Clinically Isolated Syndrome
• Relapse-Remitting Multiple Sclerosis
• Primary Progressive Multiple Sclerosis
• Secondary Progressive Multiple Sclerosis
• 6.3. Global Multiple Sclerosis Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Injectable
• Intravenous
• 6.4. Global Multiple Sclerosis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• 6.5. Global Multiple Sclerosis Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Specialty Clinics
• Homecare
• Other End-Users
• 6.6. Global Multiple Sclerosis Treatment Market, Sub-Segmentation Of Immunomodulators, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Interferon Beta-1A
• Interferon Beta-1B
• Glatiramer Acetate
• 6.7. Global Multiple Sclerosis Treatment Market, Sub-Segmentation Of Corticosteroids, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Methylprednisolone
• Prednisone
• Dexamethasone
• 6.8. Global Multiple Sclerosis Treatment Market, Sub-Segmentation Of Symptomatic Treatments, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Muscle Relaxants
• Antidepressants
• Anticonvulsants
• Bladder Dysfunction Drugs
• 6.9. Global Multiple Sclerosis Treatment Market, Sub-Segmentation Of Monoclonal Antibodies, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Natalizumab
• Ocrelizumab
• Alemtuzumab
• Ofatumumab
• 6.10. Global Multiple Sclerosis Treatment Market, Sub-Segmentation Of Oral Therapies, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Fingolimod
• Dimethyl Fumarate
• Teriflunomide
• Cladribine
• Siponimod

7. Multiple Sclerosis Treatment Market Regional And Country Analysis

• 7.1. Global Multiple Sclerosis Treatment Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Multiple Sclerosis Treatment Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Multiple Sclerosis Treatment Market

• 8.1. Asia-Pacific Multiple Sclerosis Treatment Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Multiple Sclerosis Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Multiple Sclerosis Treatment Market, Segmentation By DiseaseType, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Multiple Sclerosis Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Multiple Sclerosis Treatment Market

• 9.1. China Multiple Sclerosis Treatment Market Overview
• 9.2. China Multiple Sclerosis Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Multiple Sclerosis Treatment Market, Segmentation By DiseaseType, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Multiple Sclerosis Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Multiple Sclerosis Treatment Market

• 10.1. India Multiple Sclerosis Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Multiple Sclerosis Treatment Market, Segmentation By DiseaseType, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Multiple Sclerosis Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Multiple Sclerosis Treatment Market

• 11.1. Japan Multiple Sclerosis Treatment Market Overview
• 11.2. Japan Multiple Sclerosis Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Multiple Sclerosis Treatment Market, Segmentation By DiseaseType, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Multiple Sclerosis Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Multiple Sclerosis Treatment Market

• 12.1. Australia Multiple Sclerosis Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Multiple Sclerosis Treatment Market, Segmentation By DiseaseType, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Multiple Sclerosis Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Multiple Sclerosis Treatment Market

• 13.1. Indonesia Multiple Sclerosis Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Multiple Sclerosis Treatment Market, Segmentation By DiseaseType, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Multiple Sclerosis Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Multiple Sclerosis Treatment Market

• 14.1. South Korea Multiple Sclerosis Treatment Market Overview
• 14.2. South Korea Multiple Sclerosis Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Multiple Sclerosis Treatment Market, Segmentation By DiseaseType, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Multiple Sclerosis Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Multiple Sclerosis Treatment Market

• 15.1. Western Europe Multiple Sclerosis Treatment Market Overview
• 15.2. Western Europe Multiple Sclerosis Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Multiple Sclerosis Treatment Market, Segmentation By DiseaseType, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Multiple Sclerosis Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Multiple Sclerosis Treatment Market

• 16.1. UK Multiple Sclerosis Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Multiple Sclerosis Treatment Market, Segmentation By DiseaseType, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Multiple Sclerosis Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Multiple Sclerosis Treatment Market

• 17.1. Germany Multiple Sclerosis Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Multiple Sclerosis Treatment Market, Segmentation By DiseaseType, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Multiple Sclerosis Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Multiple Sclerosis Treatment Market

• 18.1. France Multiple Sclerosis Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Multiple Sclerosis Treatment Market, Segmentation By DiseaseType, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Multiple Sclerosis Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Multiple Sclerosis Treatment Market

• 19.1. Italy Multiple Sclerosis Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Multiple Sclerosis Treatment Market, Segmentation By DiseaseType, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Multiple Sclerosis Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Multiple Sclerosis Treatment Market

• 20.1. Spain Multiple Sclerosis Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Multiple Sclerosis Treatment Market, Segmentation By DiseaseType, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Multiple Sclerosis Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Multiple Sclerosis Treatment Market

• 21.1. Eastern Europe Multiple Sclerosis Treatment Market Overview
• 21.2. Eastern Europe Multiple Sclerosis Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Multiple Sclerosis Treatment Market, Segmentation By DiseaseType, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Multiple Sclerosis Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Multiple Sclerosis Treatment Market

• 22.1. Russia Multiple Sclerosis Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Multiple Sclerosis Treatment Market, Segmentation By DiseaseType, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Multiple Sclerosis Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Multiple Sclerosis Treatment Market

• 23.1. North America Multiple Sclerosis Treatment Market Overview
• 23.2. North America Multiple Sclerosis Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Multiple Sclerosis Treatment Market, Segmentation By DiseaseType, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Multiple Sclerosis Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Multiple Sclerosis Treatment Market

• 24.1. USA Multiple Sclerosis Treatment Market Overview
• 24.2. USA Multiple Sclerosis Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Multiple Sclerosis Treatment Market, Segmentation By DiseaseType, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Multiple Sclerosis Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Multiple Sclerosis Treatment Market

• 25.1. Canada Multiple Sclerosis Treatment Market Overview
• 25.2. Canada Multiple Sclerosis Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Multiple Sclerosis Treatment Market, Segmentation By DiseaseType, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Multiple Sclerosis Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Multiple Sclerosis Treatment Market

• 26.1. South America Multiple Sclerosis Treatment Market Overview
• 26.2. South America Multiple Sclerosis Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Multiple Sclerosis Treatment Market, Segmentation By DiseaseType, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Multiple Sclerosis Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Multiple Sclerosis Treatment Market

• 27.1. Brazil Multiple Sclerosis Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Multiple Sclerosis Treatment Market, Segmentation By DiseaseType, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Multiple Sclerosis Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Multiple Sclerosis Treatment Market

• 28.1. Middle East Multiple Sclerosis Treatment Market Overview
• 28.2. Middle East Multiple Sclerosis Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Multiple Sclerosis Treatment Market, Segmentation By DiseaseType, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Multiple Sclerosis Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Multiple Sclerosis Treatment Market

• 29.1. Africa Multiple Sclerosis Treatment Market Overview
• 29.2. Africa Multiple Sclerosis Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Multiple Sclerosis Treatment Market, Segmentation By DiseaseType, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Multiple Sclerosis Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Multiple Sclerosis Treatment Market Competitive Landscape And Company Profiles

• 30.1. Multiple Sclerosis Treatment Market Competitive Landscape
• 30.2. Multiple Sclerosis Treatment Market Company Profiles
  • 30.2.1. Johnson & Johnson Services Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. F. Hoffmann-La Roche Ltd Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Merck And Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Bayer AG Overview, Products and Services, Strategy and Financial Analysis

31. Multiple Sclerosis Treatment Market Other Major And Innovative Companies

• 31.1. Novartis AG
• 31.2. Sanofi S.A.
• 31.3. Bristol-Myers Squibb Company
• 31.4. GlaxoSmithKline plc
• 31.5. Eli Lilly and Company
• 31.6. Teva Pharmaceutical Industries Ltd.
• 31.7. Mylan N.V.
• 31.8. Biogen Inc.
• 31.9. UCB S.A.
• 31.10. Mallinckrodt Pharmaceuticals
• 31.11. Acorda Therapeutics Inc.
• 31.12. Adamas Pharmaceuticals Inc.
• 31.13. Mapi Pharma Ltd.
• 31.14. TG Therapeutics Inc.
• 31.15. Atara Biotherapeutics Inc.

32. Global Multiple Sclerosis Treatment Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Multiple Sclerosis Treatment Market

34. Recent Developments In The Multiple Sclerosis Treatment Market

35. Multiple Sclerosis Treatment Market High Potential Countries, Segments and Strategies

• 35.1 Multiple Sclerosis Treatment Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Multiple Sclerosis Treatment Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Multiple Sclerosis Treatment Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer